semaglutide cardiovascular news Insights into research: Mechanisms, trials, and frontiers US study confirms cardiovascular benefits

These behavioral approaches work synergistically with whatever appetite suppression your medication provides

If you are on semaglutide and are experiencing severe nausea, your provider may consider switching you to tirzepatide (Zepbound, Mounjaro), which has a GIP component that can reduce nausea

Metabolic indicators that may be associated with reduced GLP-1 activity include: Persistent elevated blood glucose levels , particularly postprandial (after-meal) hyperglycaemia Difficulty achieving or maintaining a healthy weight despite dietary efforts Increased appetite and reduced satiety after meals, leading to frequent snacking Diagnosis of type 2 diabetes or non-diabetic hyperglycaemia (NDH, sometimes called prediabetes), conditions where GLP-1 response is often blunted Features of metabolic syndrome , including central obesity, hypertension, and dyslipidaemia Individuals may also notice practical symptoms such as feeling hungry shortly after eating substantial meals, experiencing energy crashes following carbohydrate-rich foods, or finding portion control particularly challenging

These molecular differences could explain the slightly different dry mouth profiles between medications

But how much